HUE063047T2 - Rákellenes gyógyszerkészítmények kombinált terápiához - Google Patents

Rákellenes gyógyszerkészítmények kombinált terápiához

Info

Publication number
HUE063047T2
HUE063047T2 HUE19721103A HUE19721103A HUE063047T2 HU E063047 T2 HUE063047 T2 HU E063047T2 HU E19721103 A HUE19721103 A HU E19721103A HU E19721103 A HUE19721103 A HU E19721103A HU E063047 T2 HUE063047 T2 HU E063047T2
Authority
HU
Hungary
Prior art keywords
pharmaceutical compositions
combined therapy
anticancer pharmaceutical
anticancer
therapy
Prior art date
Application number
HUE19721103A
Other languages
English (en)
Inventor
Giuseppe Merlino
Mario Bigioni
Monica Binaschi
Andrea Pellacani
Original Assignee
Berlin Chemie Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Berlin Chemie Ag filed Critical Berlin Chemie Ag
Publication of HUE063047T2 publication Critical patent/HUE063047T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HUE19721103A 2018-03-29 2019-03-28 Rákellenes gyógyszerkészítmények kombinált terápiához HUE063047T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT102018000004082A IT201800004082A1 (it) 2018-03-29 2018-03-29 Composizioni farmaceutiche antitumorali per terapia combinata

Publications (1)

Publication Number Publication Date
HUE063047T2 true HUE063047T2 (hu) 2023-12-28

Family

ID=62875088

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE19721103A HUE063047T2 (hu) 2018-03-29 2019-03-28 Rákellenes gyógyszerkészítmények kombinált terápiához

Country Status (28)

Country Link
US (1) US20210015826A1 (hu)
EP (1) EP3773595B1 (hu)
JP (1) JP7460596B2 (hu)
KR (1) KR20200138294A (hu)
CN (1) CN111918656B (hu)
AU (1) AU2019244793A1 (hu)
BR (1) BR112020019712A2 (hu)
CL (1) CL2020002424A1 (hu)
DK (1) DK3773595T3 (hu)
EA (1) EA202092008A1 (hu)
ES (1) ES2954502T3 (hu)
FI (1) FI3773595T3 (hu)
HR (1) HRP20231131T1 (hu)
HU (1) HUE063047T2 (hu)
IL (1) IL277649A (hu)
IT (1) IT201800004082A1 (hu)
LT (1) LT3773595T (hu)
MX (1) MX2020010084A (hu)
PH (1) PH12020551583A1 (hu)
PL (1) PL3773595T3 (hu)
PT (1) PT3773595T (hu)
RS (1) RS64639B1 (hu)
RU (1) RU2020131376A (hu)
SG (1) SG11202009483YA (hu)
SI (1) SI3773595T1 (hu)
TW (1) TWI816768B (hu)
UA (1) UA127288C2 (hu)
WO (1) WO2019186451A1 (hu)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113368114B (zh) * 2020-03-10 2022-04-22 四川大学 一种吗啉嘧啶类化合物的抗肿瘤应用
WO2024023766A1 (en) * 2022-07-28 2024-02-01 Berlin-Chemie Ag P13k inhibitor combination therapy

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7932026B2 (en) * 2004-06-04 2011-04-26 Genentech, Inc. EGFR mutations
TW200938201A (en) * 2008-02-07 2009-09-16 Chugai Pharmaceutical Co Ltd Pyrrolopyrimidine derivative as PI3K inhibitor and use thereof
EA201300341A1 (ru) * 2010-09-16 2013-09-30 Шимода Байотек (Пти) Лтд. Композиция фулвестранта и способы применения
WO2012118978A1 (en) * 2011-03-03 2012-09-07 The Regents Of The University Of Colorado, A Body Corporate Methods for treating oncovirus positive cancers
US20130123255A1 (en) * 2011-11-10 2013-05-16 Chugai Seiyaku Kabushiki Kaisha Combination of a pi3k inhibitor and a mek inhibitor
US20150352076A1 (en) * 2013-01-25 2015-12-10 Toshiyuku SAKAI Molecularly targeted combination drug for tumor treatment and prevention
EP2968294B1 (en) * 2013-03-13 2019-05-01 Oncoceutics, Inc. 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-on for use in the treatment of cancer
WO2014203129A1 (en) * 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Combinations of benzopyran compounds, compositions and uses thereof
WO2015069217A1 (en) * 2013-11-05 2015-05-14 Baylor College Of Medicine Src kinase inhibition as treatment for lympangioleiomyomatosis and tuberous sclerosis
WO2015095807A1 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of egfr and erk inhibitors
FR3033499A1 (fr) * 2015-03-11 2016-09-16 Centre Leon-Berard Composition pour le traitement des tumeurs neuroendocrines pancreatiques
WO2016193955A1 (en) * 2015-06-04 2016-12-08 Giorgio Stassi Combinations of kinase inhibitors for treating colorectal cancer

Also Published As

Publication number Publication date
WO2019186451A1 (en) 2019-10-03
RS64639B1 (sr) 2023-10-31
HRP20231131T1 (hr) 2024-01-05
EP3773595A1 (en) 2021-02-17
US20210015826A1 (en) 2021-01-21
CN111918656A (zh) 2020-11-10
KR20200138294A (ko) 2020-12-09
SG11202009483YA (en) 2020-10-29
EP3773595B1 (en) 2023-07-12
JP2021519821A (ja) 2021-08-12
TW202002984A (zh) 2020-01-16
PL3773595T3 (pl) 2023-11-27
PT3773595T (pt) 2023-09-07
PH12020551583A1 (en) 2021-09-13
DK3773595T3 (da) 2023-09-18
SI3773595T1 (sl) 2023-11-30
BR112020019712A2 (pt) 2021-02-09
FI3773595T3 (fi) 2023-09-01
JP7460596B2 (ja) 2024-04-02
LT3773595T (lt) 2023-09-25
EA202092008A1 (ru) 2021-01-18
CN111918656B (zh) 2023-08-08
IL277649A (en) 2020-11-30
UA127288C2 (uk) 2023-07-12
TWI816768B (zh) 2023-10-01
ES2954502T3 (es) 2023-11-22
AU2019244793A1 (en) 2020-10-08
RU2020131376A (ru) 2022-04-29
IT201800004082A1 (it) 2019-09-29
MX2020010084A (es) 2021-01-15
CL2020002424A1 (es) 2021-03-12

Similar Documents

Publication Publication Date Title
IL290823A (en) Pharmaceutical preparations for combination therapy
ZA201906613B (en) Pharmaceutical compositions for combination therapy
IL268316B (en) Pharmaceutical preparations for combined treatment
PT3616720T (pt) Composição medicinal para tratamento de cancro
ZA201905510B (en) Pharmaceutical compositions for combination therapy
IL261278A (en) Pharmaceutical compositions for the treatment of cancer
GB201804548D0 (en) Pharmaceutical compositions
EP3708173A4 (en) THERAPEUTIC PHARMACEUTICAL COMPOSITION FOR CANCER COMPRISING A miRNA
IL275525A (en) A pharmaceutical preparation for the treatment of cancer
IL277649A (en) Preparations for the treatment of cancer by combining active substances
IL268708B (en) Pharmaceutical preparations for combined treatment
GB201808571D0 (en) Pharmaceutical compositions
HUE064434T2 (hu) Gyógyászati készítmény
EP4081251A4 (en) PHARMACEUTICAL COMPOSITIONS
GB201808567D0 (en) Pharmaceutical compositions
EP3492082A4 (en) ANTI-CANCER PHARMACEUTICAL COMPOSITION
IL286700A (en) Combined treatment against cancer
GB201719584D0 (en) Pharmaceutical compositions for the treatment of cancer
EP4066852A4 (en) PHARMACEUTICAL COMPOSITION
GB201810109D0 (en) Pharmaceutical compositions
GB201814764D0 (en) Pharmaceutical compositions for the treatment of proteinopathies
GB201810261D0 (en) New pharmaceutical compositions
GB201810265D0 (en) New pharmaceutical compositions
GB201714241D0 (en) Pharmaceutical compositions for the treatment of proteinopathies